ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1235

Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND

Désirée van der Heijde1, Cynthia E Kartman2, Li Xie2, Scott Beattie2, Douglas Schlichting2, Patrick Durez3, Yoshiya Tanaka4 and Roy Fleischmann5, 1Leiden University Medical Center, Leiden, Netherlands, 2Eli Lilly and Company, Indianapolis, IN, 3Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 4The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 5Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

Meeting: ACR Convergence 2020

Keywords: Joint Structure, radiography, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of radiographic progression for up to 2 years in patients with rheumatoid arthritis (RA). The objective of this paper is to evaluate radiographic progression of structural joint damage in patients with RA over 5 years of treatment with BARI.

Methods: This study included patients who completed three phase 3 trials, RA-BEGIN (DMARD-naïve), RA-BUILD (csDMARD-IR) or RA-BEAM (MTX-IR), and enrolled in the long-term extension study, RA-BEYOND. Patients receiving blinded BARI at the conclusion of phase 3 trials remained on that dose (2mg or 4mg, once daily) in RA-BEYOND. At 52 weeks, DMARD-naïve patients receiving methotrexate (MTX) or combination therapy (BARI 4mg + MTX) were switched to BARI 4mg monotherapy; MTX-IR patients receiving adalimumab (ADA) were switched to BARI 4mg on background MTX. At 24 weeks, csDMARD-IR patients receiving placebo (PBO) were switched to BARI 4mg on background csDMARD. Analysis population included patients who had baseline and at least one radiograph collected after 2 years. Radiographic progression of structural joint damage (Years 3-5) was determined by changes from baseline in van der Heijde modified Total Sharp Score (ΔmTSS), erosion score, and joint space narrowing. Proportion of patients showing no progression was assessed based on change from baseline mTSS (Δ mTSS) from the originating study, using thresholds of 0.5 or the smallest detectable change (SDC). Mixed model repeated measures and logistic regression models were used to analyze continuous variables and categorical variables, respectively; linear extrapolation was used for imputation of missing data (maximum of 1 year).

Results: Overall, 82.6% (2125/2573) of patients entered the long-term extension study. Among DMARD-naïve patients, those on initial BARI monotherapy or in combination with MTX had significantly slower radiographic progression (ΔmTSS) compared to those on initial MTX at years 3, 4, and 5 (Table 1; p≤0.05). These patients also had significantly fewer erosions at these time points (p≤0.05). A greater proportion of patients who had received initial BARI therapy and BARI in combination with MTX had no radiographic progression compared to initial MTX monotherapy using thresholds of 0.5 (Table 2; p≤0.05). Among MTX-IR patients, patients on initial BARI treatment had slower radiographic progression compared to PBO and the results were comparable to those on initial adalimumab treatment at years 3, 4, and 5 (Table 1). A greater proportion of patients who had received initial BARI therapy had no radiographic progression compared to initial PBO using thresholds of SDC (Table 2; p≤0.05). Among csDMARD-IR patients, although differences between groups were small, patients on initial BARI 4mg had slowest radiographic progression compared to initial PBO and initial BARI 2mg (Table 1). At least 74% of the structure data used in the analyses are based on observed data.

Conclusion: Treatment with once-daily oral BARI maintained low rates of radiographic progression for up to 5 years in different patient populations with RA.

Table 1: Changes from baseline in mTSS and its components in different patient populations

Table 2: Percentage of patients without structural damage progression in different patient populations


Disclosure: D. van der Heijde, AbbVie, 5, Bristol-Myers Squibb, 5, Cyxone, 5, Galapagos NV, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5, UCB Pharma, 5, Amgen Inc., 5, Astellas, 5, AstraZeneca, 5, Boehringer Ingelheim, 5, Celgene, 5, Daiichi-Sankyo, 5, Janssen, 5, Merck, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Takeda, 5, Imaging Rheumatology bv, 3, Eisai, 5; C. Kartman, Eli Lilly and Company, 1, 3; L. Xie, Eli Lilly and Company, 1, 3; S. Beattie, Eli Lilly and Company, 1, 3; D. Schlichting, Eli Lilly and Company, 1, 2; P. Durez, None; Y. Tanaka, AbbVie, 2, 5, 8, UCB, 2, 5, 8, Sanofi, 2, 5, 8, Asahi-kasei, 2, 5, 8, Novartis, 2, 5, 8, GlaxoSmithKline, 2, 5, 8, Astellas, 2, 5, 8, Chugai, 2, 5, 8, Daiichi-Sankyo, 2, 5, 8, Eisai, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead Sciences, Inc., 2, 5, 8, Janssen, 2, 5, 8, Mitsubishi-Tanabe, 2, 5, 8, Pfizer, 2, 5, 8, Takeda, 2, 5, 8, YL Biologics, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8; R. Fleischmann, Pfizer, 2, 5.

To cite this abstract in AMA style:

van der Heijde D, Kartman C, Xie L, Beattie S, Schlichting D, Durez P, Tanaka Y, Fleischmann R. Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/radiographic-progression-of-structural-joint-damage-over-5-years-of-baricitinib-treatment-in-patients-with-rheumatoid-arthritis-results-from-ra-beyond/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiographic-progression-of-structural-joint-damage-over-5-years-of-baricitinib-treatment-in-patients-with-rheumatoid-arthritis-results-from-ra-beyond/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology